At-Home Colon Cancer Screening Test Maker Security Risk Assessment Guide

What security risks should an at-home colon cancer test maker assess?

An at-home screening product can involve more than a physical test kit. A maker may handle order and shipping details, eligibility questionnaires, specimen identifiers, laboratory workflows, test results, online accounts, and communications. Start the assessment by mapping where each type of information is collected, stored, used, shared, and deleted—including systems operated by laboratories and other vendors.

Assess risks across confidentiality, integrity, and availability: who could view or disclose information without authorization, how a sample or result could be altered or matched to the wrong person, and how a system outage or ransomware event could interrupt testing or reporting. The HHS summary of the HIPAA Security Rule describes the risk-analysis duties that apply to HIPAA-regulated entities and explains that safeguards should be based on identified risks.

• Account and application risks: stolen passwords, credential stuffing, phishing, weak account recovery, and insecure interfaces between the website, app, laboratory, or health record.
• Laboratory and specimen risks: unauthorized facility access, exposed workstations, lost or mislabeled specimens, barcode mix-ups, and incorrect matching of a result to a user.
• Data and infrastructure risks: misconfigured cloud storage, unpatched software, excessive staff access, insecure backups, and inadequate monitoring.
• Disclosure risks: information reaching an unintended recipient through analytics tools, advertising trackers, support systems, email, or a vendor’s subcontractor.
• Service continuity risks: a cyberattack, equipment failure, or vendor outage delaying specimen processing, result delivery, or access to records.

Record each risk, the information and systems affected, its likelihood and potential impact, existing safeguards, remaining risk, and the owner and deadline for mitigation. Review the assessment when the maker adds a product feature, changes a laboratory or cloud provider, or discovers a new threat. HIPAA’s Security Rule applies to covered entities and business associates—not automatically to every company that sells a consumer test—so first establish which laws and roles apply.

How does the test maker collect and protect health and genetic data?

Document what the product actually collects rather than relying on a broad label such as “health data.” Depending on the test and service, information may include a person’s name and contact details, shipping and payment information, questionnaire responses, family or medical history, specimen identifiers, laboratory records, test results, customer-support messages, and account or device data. A colon cancer screening test does not necessarily involve genetic testing; if a product does collect genetic or family-history information, describe that specifically.

HHS explains that genetic information is protected health information when it is individually identifiable and maintained by a HIPAA-covered health care provider, health plan, or clearinghouse. Whether information is protected health information under HIPAA depends on the entity and context, not simply on the sensitivity of the data. See HHS guidance on genetic information and HIPAA.

For each data element, record why it is needed, where it goes, who can use it, and how long it is retained. Collect only information needed for the stated service, separate direct identifiers from laboratory records where practical, and explain any secondary uses such as research, product improvement, or marketing. The FTC’s mobile health app best practices recommend minimizing collection and carefully reviewing third-party software and permissions; treat these as recommended practices, not as a substitute for determining applicable legal requirements.

Protect information throughout its lifecycle, including during collection, specimen processing, result delivery, backup, archival, and disposal. If the maker or its laboratory is HIPAA-regulated, assess whether the information is electronic protected health information and whether the Security Rule applies. If the maker is not HIPAA-regulated, do not imply that HIPAA protections automatically cover its direct-to-consumer records; other federal or state requirements may still apply.

Which cybersecurity controls protect test kits, accounts, and connected systems?

Build controls around the risks identified in the assessment, spanning people, physical facilities, software, and data. For clinical laboratory data security, also consider how the maker prevents specimen identity errors: use unique identifiers, verify handoffs, restrict label creation and changes, and reconcile specimen and result records before release. These are risk-management measures to evaluate for the particular workflow.

• Identity and access: use unique staff accounts, multifactor authentication for sensitive or administrative access, prompt removal of access when roles change, and role-based access control that limits each user to the information needed for their duties.
• Encryption: evaluate encryption at rest and in transit for databases, backups, portable devices, lab connections, and user sessions. Under HIPAA, encryption is an addressable implementation specification: the entity must assess whether it is reasonable and appropriate, implement it when appropriate, or document and use a suitable alternative. See the HHS Security Rule summary.
• Monitoring and integrity: log access to sensitive records, review alerts for unusual activity, protect logs from alteration, and use checks that help detect unauthorized changes to result or specimen records.
• Secure development and operations: test applications and interfaces, fix vulnerabilities, manage software updates, protect secrets and keys, and separate development and production environments.
• Physical and operational safeguards: restrict access to laboratory and equipment areas, secure workstations and removable media, train staff, and maintain tested backup and recovery procedures.
• Customer accounts and communications: provide secure account recovery, avoid exposing results in notification previews, and use secure channels for delivering sensitive reports.

Do not treat a single control—such as encryption or multifactor authentication—as a complete security program. HHS describes the HIPAA Security Rule as technology-neutral and risk-based, with administrative, physical, and technical safeguards; its current requirements should be distinguished from any proposed regulatory changes.

How should the maker assess vendors and third-party data sharing?

Maintain an inventory of laboratories, cloud and hosting providers, shipping services, payment processors, customer-support platforms, analytics tools, and other vendors that may handle kit or health information. For each, identify the data involved, the service provided, the locations and systems used, subcontractors, access privileges, retention practices, and the consequences if the vendor is unavailable or compromised. This is the core of third-party risk management.

When a HIPAA-covered entity engages a vendor to create, receive, maintain, or transmit protected health information on its behalf, the relationship may require a written HIPAA business associate agreement. The agreement should define permitted uses and disclosures, safeguard duties, subcontractor obligations, incident reporting, and what happens to information when the service ends. HHS explains that covered entities must have a written business associate contract or arrangement when they engage a business associate; see HHS guidance on covered entities and business associates.

A business associate agreement is not a general privacy certification, and signing one does not by itself establish that a vendor’s controls are adequate. For vendors outside a HIPAA business associate relationship, use appropriate privacy and security terms for the actual arrangement. Require clear limits on data use and onward sharing, timely incident notice, cooperation with investigations and user requests, reasonable security evidence, and secure return or disposal of data at contract end.

Review tracking technologies and data flows in websites and apps, including whether analytics or advertising tools receive information that can reveal someone’s use of a screening service. Explain sharing in plain language and obtain consent where required. The FTC’s app developer guidance advises developers to review third-party code and permissions and to avoid accessing information they do not need.

What incident response and breach notification procedures are required?

Maintain a written response plan that covers suspected and confirmed incidents involving accounts, websites, laboratory systems, physical kits, vendors, and accidental disclosures. The plan should identify decision-makers and contacts, preserve evidence, contain access, assess which information and individuals were affected, coordinate with laboratories and service providers, restore operations safely, and document decisions. Run exercises so teams know who investigates, who makes notification decisions, and how users can reach the organization.

Notification duties depend on which law applies and the organization’s role. Under HIPAA, a covered entity must notify affected individuals after a breach of unsecured protected health information without unreasonable delay and no later than 60 days after discovery. Business associates must notify the covered entity under the applicable rule and contract. HHS summarizes these requirements, including notices to HHS and, in certain circumstances, the media, in its HIPAA Breach Notification Rule guidance.

A maker that is not covered by HIPAA may still need to assess the FTC’s Health Breach Notification Rule. The Rule applies to specified entities, including certain vendors of personal health records and related service providers; it does not automatically apply to every test-kit seller. Where it applies, the FTC says affected people must be notified without unreasonable delay and within 60 calendar days after discovery. FTC reporting deadlines vary by the number affected, and media notice may also be required. See the FTC guide to complying with the Health Breach Notification Rule.

Prepare notification templates and escalation steps in advance, but confirm the facts and applicable rule before sending notices. A clear notice should explain what happened, what types of information were involved, what the organization is doing, what steps people can take, and how to get help. For a breach involving laboratory results or other sensitive health information, coordinate with the laboratory and any responsible covered entity so that notifications are accurate and consistent.

How can patients review privacy practices and exercise their rights?

Patients can look for a privacy notice that identifies the information collected, the reasons for collection, who receives it, how long it is kept, and how to contact the maker about access, correction, sharing, or deletion. Check whether the policy separately explains laboratory handling, optional research, advertising or analytics, and account closure. A privacy notice describes practices; it does not by itself prove that a company is HIPAA-covered or that its safeguards have been independently verified.

If the records are held by a HIPAA-covered provider or health plan, patients generally have a right to access health information in the entity’s designated record set, subject to limited exceptions, and may request an amendment to information they believe is inaccurate or incomplete. HHS notes that these rights can include clinical laboratory test reports held by or for a covered entity. See HHS guidance on information individuals may access under HIPAA.

HIPAA does not create a general right to have a medical record deleted. The HIPAA Privacy Rule also does not set medical-record retention periods; state law generally governs how long records must be kept, and safeguards continue to apply while records are maintained. A patient can still ask the maker to delete an account or information, but whether the request must be honored depends on the company’s role, applicable law, retention duties, and privacy policy. See HHS guidance on HIPAA and record retention.

In short, a trustworthy security assessment traces data from kit purchase through laboratory processing and result delivery, tests the controls and vendors at each step, and explains clearly which privacy rights and breach rules apply. Patients can use the maker’s privacy notice and contact channels to understand the handling of their information and submit requests to the organization that holds the relevant records.

FAQs

Is an at-home colon cancer screening test maker subject to HIPAA?

Not automatically. HIPAA applies to covered entities—such as certain health care providers that conduct specified electronic transactions—and their business associates. A test maker may be covered if it qualifies as one of these entities or performs services involving protected health information on behalf of a covered entity. A direct-to-consumer maker that is not covered by HIPAA may still have obligations under other laws, including the FTC’s Health Breach Notification Rule if it falls within that rule’s scope. See HHS’s explanation of covered entities and business associates and the FTC’s Health Breach Notification Rule guidance.

What personal and health information can an at-home screening test maker collect?

Depending on its test and services, a maker may collect contact and shipping details, payment information, eligibility or health questionnaire responses, specimen identifiers, laboratory records, test results, account information, and customer-support communications. Some products may collect family-history or genetic information, but that is not inherent to every colon cancer screening test. Review the maker’s privacy notice for its actual collection and sharing practices.

How should a screening test maker notify users after a data breach?

It must first determine which notification law applies, what information was involved, and who was affected. HIPAA-covered entities generally must notify affected individuals without unreasonable delay and no later than 60 days after discovery of a breach of unsecured protected health information. If the FTC Health Breach Notification Rule applies, it generally requires notice to affected people without unreasonable delay and within 60 days; FTC and media notice requirements depend on the number and location of affected people. The notice should clearly explain what happened, what information was involved, what steps users can take, and how to get assistance. See the HHS breach notification guidance and the FTC rule guidance.

Can patients request deletion of their screening test data?

Yes, patients can ask the maker to delete their information, but a request is not always a legal right to deletion. HIPAA provides access and amendment rights for covered records but does not provide a general deletion right, and state laws or other applicable requirements may affect what a maker must delete or retain. Ask the company what information it can delete, what it must retain, and how long retained records remain protected.